Marker Therapeutics, Inc.

Tagged: HER2neu vaccine

TAPIMMUNE ANNOUNCES FINALIZATION OF LICENSE AGREEMENT WITH MAYO CLINIC TO COMMERCIALIZE A HER2neu VACCINE

…Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials

Jacksonville FL, June 7, 2016 – TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company is pleased to announce that the Company has exercised its option agreement with Mayo Clinic and signed a worldwide license agreement to a proprietary HER2neu vaccine technology.

Read More